Skip to content

Dexmedetomidine for prevention of postoperative pulmonary complications in patients after oral and maxillofacial surgery with fibular free flap reconstruction

Dexmedetomidine for prevention of postoperative pulmonary complications in patients after oral and maxillofacial surgery with fibular free flap reconstruction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016153
Enrollment
Unknown
Registered
2020-05-31
Start date
2018-09-01
Completion date
Unknown
Last updated
2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pulmonary complications

Interventions

B:normal saline

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
51 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) To be scheduled for oral and maxillofacial surgery with fibular free flap reconstruction that was expected to exceed 3 hours under general anesthesia; (2) Aged 51 years old or over; (3) took tracheotomy before the end of the surgery; (4) had an intermediate to high risk of developing PPCs judged by Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score(cumulative ARISCAT risk score were 26 or greater).

Exclusion criteria

Exclusion criteria: (1) body mass index of 35 or higher; (2) allergic to DEX; (3) recent sedatives-taking history; (4) sick sinus syndrome, or severe sinus bradycardia(<50 beats per min[bpm]), or second degree or greater atrioventricular block without pacemaker; (5) previous lung surgery history, or severe chest wall malformation, or acute exacerbation of chronic obstructive pulmonary disease (AECOPD), or uncontrolled asthma (Asthma control test = 18), or pulmonary artery stenosis, or pulmonary hypertension; (6) complex heart deformities, congestive heart failure, or known preoperative left ventricular ejection fraction less than 30%; (7) serious hepatic dysfunction(Child-Pugh class C), or serious renal dysfunction(requirement of renal replacement therapy); (8) a history of mental illness; (9) refused to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
postoperative pulmonary complications;

Countries

China

Contacts

Public ContactYun Liu

Peking University Hospital of Stomatology

docsusieliu@hotmail.com+86 13426341446

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026